These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23027412)

  • 1. Behavioral animal models to assess pro-cognitive treatments for schizophrenia.
    Young JW; Amitai N; Geyer MA
    Handb Exp Pharmacol; 2012; (213):39-79. PubMed ID: 23027412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
    Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
    Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.
    Barak S; Weiner I
    Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries.
    Silverstein SM; Jaeger J; Donovan-Lepore AM; Wilkniss SM; Savitz A; Malinovsky I; Hawthorne D; Raines S; Carson S; Marcello S; Zukin SR; Furlong S; Dent G
    J Clin Exp Neuropsychol; 2010 Nov; 32(9):937-52. PubMed ID: 20455131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Measuring the cognitive deficit associated with schizophrenia: presentation of the MATRICS neuropsychological test battery].
    Sarolta K; Pál C; István B
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):143-50. PubMed ID: 18399033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive impairment in schizophrenia.
    Keefe RS; Harvey PD
    Handb Exp Pharmacol; 2012; (213):11-37. PubMed ID: 23027411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting drug efficacy for cognitive deficits in schizophrenia.
    Hagan JJ; Jones DN
    Schizophr Bull; 2005 Oct; 31(4):830-53. PubMed ID: 16177277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
    Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P
    Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia.
    Pietrzak RH; Olver J; Norman T; Piskulic D; Maruff P; Snyder PJ
    J Clin Exp Neuropsychol; 2009 Oct; 31(7):848-59. PubMed ID: 19142774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of attention on an auditory-verbal learning test in schizophrenic patients].
    Huguelet P; Nicastro R; Zanello A
    Encephale; 2002; 28(4):291-7. PubMed ID: 12232538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].
    Rodríguez-Jiménez R; Bagney A; Moreno-Ortega M; García-Navarro C; Aparicio AI; López-Antón R; de la Oliva J; Jiménez-Arriero MÁ; Santos JL; Lobo A; Palomo T
    Rev Neurol; 2012 Nov; 55(9):549-55. PubMed ID: 23111994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The overlap of cognitive impairment in depression and schizophrenia: a comparative study.
    Soštarič M; Zalar B
    Psychiatr Danub; 2011 Sep; 23(3):251-6. PubMed ID: 21963692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia].
    Jedrasik-Styła M; Ciołkiewicz A; Denisiuk M; Linke M; Parnowska D; Gruszka A; Jarema M; Wichniak A
    Psychiatr Pol; 2012; 46(2):261-71. PubMed ID: 23214396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
    Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
    Floresco SB; Geyer MA; Gold LH; Grace AA
    Schizophr Bull; 2005 Oct; 31(4):888-94. PubMed ID: 16079387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J; Demily C; Thibaut F
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.